Jeito Capital

Profile

Jeito Capital is a venture capital firm based in Paris, founded in 2018 by Dr Rafaèle Tordjman, who has a background as a hematologist-immunologist. The firm consists of over 30 team members who bring a combination of scientific and medical expertise alongside biotech financing experience. Jeito Capital is known for its patient-centric approach and strong emphasis on supporting European biopharma companies across various therapeutic areas.

Jeito Capital invests in clinical-stage biopharma companies, primarily within sectors such as obesity, oncology, immunology, neurology, reproductive medicine, and cardio-metabolic disease. The fund targets later-stage investments with check sizes up to an average of €150 million per company. Their geographical focus is primarily on Europe, with flexibility to operate transatlantically. The firm increased its assets under management to €1.6 billion following the closure of Jeito II. Key LPs include the European Investment Bank and other global strategic and institutional partners.

Notable companies in Jeito Capital's portfolio include EyeBio, which was sold to Merck for up to $3 billion, and another portfolio company involved in a transaction with Biogen, resulting in cumulative exit values of up to $4.8 billion. These successful exits highlight Jeito's ability to navigate the biotech landscape and deliver significant returns to its limited partners.